Zhangzhou Pientzehuang Pharmaceutical., Ltd

SHSE:600436 Stock Report

Market Cap: CN¥125.8b

Zhangzhou Pientzehuang Pharmaceutical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jin Ming Huang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.8yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure2.4yrs

Recent management updates

Recent updates

There's Reason For Concern Over Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

Mar 10
There's Reason For Concern Over Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Seems To Use Debt Rather Sparingly

Feb 20
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Seems To Use Debt Rather Sparingly

Is Now The Time To Put Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) On Your Watchlist?

Feb 03
Is Now The Time To Put Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) On Your Watchlist?

A Look At The Fair Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)

Dec 31
A Look At The Fair Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)

Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Share Price Could Signal Some Risk

Nov 25
Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Share Price Could Signal Some Risk

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

Nov 07
These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Oct 22
Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Estimating The Intrinsic Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)

Sep 08
Estimating The Intrinsic Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)

Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts

Aug 20
Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts

Subdued Growth No Barrier To Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

Jul 12
Subdued Growth No Barrier To Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

May 27
These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

CEO

Jin Ming Huang (58 yo)

5.8yrs

Tenure

CN¥601,700

Compensation

Mr. Jin Ming Huang is GM of Zhangzhou Pientzehuang Pharmaceutical., Ltd from July 02, 2019 and is its Director from July 02, 2019. He joined the Zhangzhou Pientzehuang Pharmaceutical., Ltd in September 200...


Board Members

NamePositionTenureCompensationOwnership
Jin Ming Huang
GM & Director9.1yrsCN¥601.70kno data
Haipeng Yang
Chief Accountant & Director3.3yrsCN¥529.50kno data
Yuhong Chen
Supervisor2.9yrsno datano data
Tengyun Wei
Supervisor7.7yrsno datano data
Shouying Du
Independent Director3.3yrsCN¥80.00kno data
Huang Yalong
Employee Supervisor3.3yrsno datano data
Shibin Xu
Chairman of Supervisory Board1.3yrsno datano data
Zhi Hui Lin
Chairman of the Board1.8yrsno datano data
Wenning Lai
Non-Independent Director1.4yrsno datano data
Lei Zhang
Independent Director1.9yrsno datano data
Zhengda Tian
Independent Director1yrno datano data
Lei Chen
Independent Director1.9yrsno datano data

2.4yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 600436's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/15 09:49
End of Day Share Price 2025/05/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhangzhou Pientzehuang Pharmaceutical., Ltd is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhe SunBofA Global Research
Zhe SunBofA Global Research
Siti Bte SalikinCFRA Equity Research